Treatment Action Group launches the 2022 Tuberculosis Diagnostics Pipeline Report.

Joint position statement and global solidarity appeal from TB communities to all TB stakeholders

With newer TB drugs to go off patent in 2023, MSF calls on Johnson & Johnson, Otsuka, and TB Alliance to remove additional barriers blocking generic manufacturers from entering the market.

Several key global health actors have already set plans into motion to answer the 1/4/6x24 Campaign call to action, making major commitments. Two countries have also stepped up as global leaders.

The Call to Action calls on the G20 member countries to ensure continuity of high-quality treatment, care and support services and programming that address the needs of the most affected and vulnerable populations, for a more efficient and effective TB response.

TB deaths increase for a second year in a row and TB incidence rises for the first time in 20 years.

'Disrupted but not defeated' - recognizing TB services providers in areas with armed conflict.

Advocates demand that the Indian government take urgent action to ensure that every eligible person with TB has access to evidence-based, short-course treatment regimens.

Treatment Action Group (TAG) launches the first TB chapter of its 2022 Pipeline Report.

The framework is meant to address the limited uptake of collaborative activities to reduce the burden of TB and comorbidities and to support countries in enabling access to people-centred care.